ClinicalTrials.Veeva

Menu

Neutralizing Antibody Level After COVID-19 Vaccination

K

Kyungpook National University

Status

Enrolling

Conditions

Covid19

Treatments

Diagnostic Test: COVID-19 neutralizing antibody

Study type

Observational

Funder types

Other

Identifiers

NCT05083026
KNUCH-2021005-001-001

Details and patient eligibility

About

  1. serial of neutralizing antibody at 2, 4, 6, 9, 12 month after COVID-19 vaccination
  2. investigate the factors on antibody titer.

Full description

  1. serial of neutralizing antibody at 2, 4, 6, 9, 12 month after COVID-19 vaccination 1) semi-quantitative measurement of neutralizing antibody at 2, 4, 6, 9, 12 month after COVID-19 vaccination 2) investigate the duration maintaining acceptable range (over 30% inhibition)
  2. investigate the factors on antibody titer at 2 month after vaccination 1) potential factors: age, sex, body weight, height, use of medication, use of antipyretics (NSAID or tyrenol), side effect of COVID-19 vaccination 2) correlation between antibody titer and potential factors
  3. Compare 4 diagnostic ELISA kit at 2 month after vaccination 1) measure neutralizung antibody using ELISA kits from 4 different companies 2) investigate correlation coefficient of antibody titer between companies

Enrollment

51 estimated patients

Sex

All

Ages

20 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • healthcare works after completion of COVID-19 vaccination
  • 20-60 years
  • sign the agreement of study

Exclusion criteria

  • serious underlying diseases

Trial contacts and locations

1

Loading...

Central trial contact

Su Youn Nam, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems